HAEMATO AG (HAM:HAEK) ROCE % : 5.48% (As of Jun. 2023)

View and export this data going back to 2006. Start your Free Trial

What is HAEMATO AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. HAEMATO AG's annualized ROCE % for the quarter that ended in Jun. 2023 was 5.48%.

HAEMATO AG ROCE % Historical Data

The historical data trend for HAEMATO AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HAEMATO AG ROCE % Chart

HAEMATO AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

9.75

-0.51

-3.77

7.22

7.36

HAEMATO AG Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROCE %	Get a 7-Day Free Trial															12.80	1.36	2.99	11.73	5.48

HAEMATO AG ROCE % Calculation

HAEMATO AG's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	10.843	/	( ( (182.01 - 37.089)	+	(176.57 - 26.773) )	/ 2 )
	=	10.843	/	( (144.921	+	149.797)	/ 2 )
	=	10.843	/	147.359
	=	7.36 %

HAEMATO AG's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	8.276	/	( ( (176.57 - 26.773)	+	(183.448 - 31.374) )	/ 2 )
	=	8.276	/	( ( 149.797	+	152.074 )	/ 2 )
	=	8.276	/	150.9355
	=	5.48 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

HAEMATO AG (HAM:HAEK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

HAEMATO AG ROCE % Related Terms

Thank you for viewing the detailed overview of HAEMATO AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

HAEMATO AG (HAM:HAEK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HAEMATO AG (HAM:HAEK) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

HAEK:Germany

Address

Lilienthalstrasse 5c, Schonefeld, DEU, D-12529

Website

https://www.haemato.ag

HAEMATO AG is a Germany based pharmaceutical company. It provides pharmaceuticals for the care of chronically ill people. The firm is engaged in the sale of generic and EU (European countries) import drugs. It is focused on patented and non-patented medicinal products. The company product portfolio includes human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), neurology, oncology, rheumatology, and urology. Geographically, it operates only in Germany.

HAEMATO AG (HAM:HAEK) Headlines

No Headlines